Gianpaolo Di Santo

Innsbruck, 6020, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience.

Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 30, 2026

Real-world outcomes of [177Lu]Lu-PSMA-I&T in [18F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.

Real-world outcomes of [177Lu]Lu-PSMA-I&T in [18F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 29, 2026

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.

Journal: Pharmaceutics

Published: December 23, 2025

Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.

Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 21, 2025

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.

Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 11, 2025

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Journal: Theranostics

Published: August 07, 2025

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial.

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 14, 2025

Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 10, 2025

Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series.

Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series.

Journal: Frontiers in oncology

Published: January 28, 2025

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.

Journal: Journal of neuroendocrinology

Published: October 18, 2024

Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 28, 2024

Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy.

Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 16, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026